Integrated sorting, concentration and real time PCR based detection system for sensitive detection of microorganisms

<p><b>(a) Time course of the disease activity score over 24 weeks following the initiation of tofacitinib treatment with or without concomitant use of MTX.</b> Data were analyzed by the LOCF method. Points represent means. * p < 0.0001 versus baseline by the Wilcoxon signed rank test. † p < 0.05 versus baseline by the Wilcoxon signed rank test. <b>(b) The proportion of disease activity at 24 weeks after initiation of tofacitinib treatment with or without concomitant use of MTX.</b> Disease activity was categorized as follows. DAS 28-ESR <2.6(remission), 2.6-≤3.2(LDA), 3.2-≤5.1(MDA), 5.1<(HDA). <i>MTX</i> methotrexate, <i>LOCF</i> last observation carried forward, <i>ESR</i> erythrocyte sedimentation rate, <i>DAS</i> disease activity score, <i>LDA</i> low disease activity, <i>MDA</i> moderate disease activity, <i>HDA</i> high disease activity.</p

The proportion of disease activity at baseline and 24 weeks after initiation of tofacitinib treatment.

<p>Disease activity was categorized as follows: DAS 28-ESR <2.6(remission), 2.6-≤3.2(LDA), 3.2-≤5.1(MDA), 5.1<(HDA); SDAI<3.3(remission), 3.3-<11(LDA), 11-≦26 (MDA), 26<(HDA); CDAI<2.8(remission), 2.8-<10(LDA), 10-≦22 (MDA), 22<(HDA); <i>ESR</i> erythrocyte sedimentation rate, <i>DAS</i> disease activity score, <i>SDAI</i> simplified disease activity index, <i>CDAI</i> clinical disease activity index, <i>LDA</i> low disease activity, <i>MDA</i> moderate disease activity, <i>HDA</i> high disease activity.</p

Comparison of baseline characteristics in patients with different backgrounds.

<p>Comparison of baseline characteristics in patients with different backgrounds.</p

Time course of disease activity scores over 24 weeks of tofacitinib treatment.

<p>Data were analyzed by the LOCF method. Points and bars represent means and standard deviations, respectively. *p < 0.0001 versus baseline by the Wilcoxon signed rank test. <i>LOCF</i> last observation carried forward, <i>ESR</i> erythrocyte sedimentation rate, <i>DAS</i> disease activity score.</p

Multivariate regression model to estimate the factors associated the achievement of LDA at 24 weeks.

<p>Multivariate regression model to estimate the factors associated the achievement of LDA at 24 weeks.</p

Clinical characteristics of the study population.

<p>Clinical characteristics of the study population.</p

Additional file 1 of Evaluating the safety profile of calcineurin inhibitors: cancer risk in patients with systemic lupus erythematosus from the LUNA registry—a historical cohort study

Additional file 1: Figure S1. Design diagram to clarify the key points of each item

Patient enrollment flow chart and the therapeutic course during the 1-year observation after the baseline in our RA cohort.

<p>HDA: high disease activity; MDA: moderate disease activity; LDA: low disease activity; csDMARDs: conventional synthetic disease-modifying antirheumatic drugs; bDMARDs: biological disease-modifying antirheumatic drugs.</p

Patients’ characteristics with disease activity (univariate analyses)^*.

<p>Patients’ characteristics with disease activity (univariate analyses)^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0175281#t005fn001" target="_blank">*</a>}.</p

Cumulative probability plots of changes in mTSS for 1 year in the ACPA-positive patients versus the ACPA-negative patients.

<p>ACPA: anti-citrullinated peptide antibodies; mTSS: modified total Sharp score.</p